Simrin Suspension 1%+0.2% is an ophthalmic combination of Brinzolamide 1% and Brimonidine Tartrate 0.2%, formulated to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. By combining two complementary mechanisms of action, Simrin provides effective and sustained lowering of IOP, helping to prevent optic nerve damage and vision loss associated with glaucoma.

Brinzolamide is a carbonic anhydrase inhibitor that reduces the production of aqueous humor in the eye, while Brimonidine Tartrate is an alpha-2 adrenergic agonist that decreases aqueous humor production and increases uveoscleral outflow. The combination offers dual-action therapy with improved efficacy compared to monotherapy, making it suitable for patients not adequately controlled with a single agent.

Simrin 1%+0.2% is a preservative-containing ophthalmic suspension, carefully formulated to ensure tolerability and stability while maintaining optimal therapeutic effect.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Simrin Suspension 1%+0.2% is indicated for:

• Open-angle glaucoma: To reduce elevated intraocular pressure and prevent optic nerve damage

• Ocular hypertension: For patients with high intraocular pressure at risk of glaucoma

• Patients inadequately controlled on monotherapy: Particularly when a combination of Brinzolamide or Brimonidine alone is insufficient

Therapeutic Class

• Ophthalmic carbonic anhydrase inhibitor and alpha-2 adrenergic agonist combination

Pharmacology

• Brinzolamide (1%): Inhibits carbonic anhydrase II in the ciliary body, reducing bicarbonate formation and consequently aqueous humor secretion. This leads to decreased intraocular pressure.

• Brimonidine Tartrate (0.2%): Selectively stimulates alpha-2 adrenergic receptors in the eye, reducing aqueous humor production and enhancing uveoscleral outflow.

• Combined effect: Dual-action therapy produces additive IOP-lowering effects, helping achieve target intraocular pressure levels with once or twice daily dosing.

The combination ensures long-lasting reduction of IOP with minimal systemic absorption, making it suitable for long-term management of glaucoma and ocular hypertension.

Dosage and Administration

• Recommended dose: Instill one drop in the affected eye(s) twice daily (approximately 12 hours apart)

• Administration tips:

  • Shake well before use to ensure proper suspension

  • Avoid contact of the dropper tip with the eye or surrounding surfaces to prevent contamination

  • Wait at least 5 minutes before instilling other ophthalmic medications in the same eye

  • Remove contact lenses before administration and wait 15 minutes before reinsertion

• Pediatric use: Safety and efficacy have not been established in patients under 18 years of age.

• Elderly use: No dose adjustment is generally necessary, but caution should be observed in patients with cardiovascular or cerebrovascular conditions.

Contraindications

• Known hypersensitivity to Brinzolamide, Brimonidine, sulfonamides, or any other components of the formulation

• Patients with severe renal impairment (due to Brinzolamide)

• Use in neonates and infants under 2 years (Brimonidine may cause severe CNS depression)

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Common adverse effects:

• Ocular: Burning or stinging sensation, blurred vision, ocular discomfort, dry eyes, conjunctival hyperemia

• Systemic: Mild headache, dizziness, or fatigue

Rare but serious side effects:

• Allergic reactions including eyelid edema, eye irritation, or pruritus

• CNS effects (drowsiness or hypotension) in sensitive patients, especially in the elderly

Precautions and Warnings

• Caution in patients with cardiovascular disease, cerebrovascular disease, or severe renal impairment

• May interact with other systemic alpha-2 agonists or CNS depressants

• Pregnancy & Lactation: Use only if clearly needed; limited data are available regarding safety in pregnant or breastfeeding women

• Patients should avoid driving or operating machinery if they experience visual disturbances or drowsiness

Storage Conditions

• Store at 2–30°C

• Protect from light and moisture

• Keep out of reach of children

Mode of Action

Simrin Suspension 1%+0.2% reduces intraocular pressure through dual mechanisms:

1. Brinzolamide decreases aqueous humor production by inhibiting carbonic anhydrase in the ciliary processes

2. Brimonidine reduces aqueous humor production via alpha-2 adrenergic receptor stimulation and enhances uveoscleral outflow

The combination ensures effective, long-term IOP control, protecting the optic nerve and maintaining vision in patients with glaucoma or ocular hypertension.